Bionexus Gene Lab Corp (BGLC)

$0.52

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $0.51
    $0.54
    $0.52
    downward going graph

    1.17%

    Downside

    Day's Volatility :4.66%

    Upside

    3.53%

    downward going graph
  • $0.31
    $9.49
    $0.52
    downward going graph

    40.38%

    Downside

    52 Weeks Volatility :96.73%

    Upside

    94.52%

    downward going graph

Returns

PeriodBionexus Gene Lab CorpIndex (Russel 2000)
3 Months
-14.32%
0.0%
6 Months
0.76%
0.0%
1 Year
-95.29%
0.0%
3 Years
-97.89%
-17.0%

Highlights

Market Capitalization
9.4M
Book Value
$0.53
Earnings Per Share (EPS)
-0.19
Profit Margin
-27.25%
Operating Margin TTM
-3.32%
Return On Assets TTM
-13.38%
Return On Equity TTM
-33.5%
Revenue TTM
9.8M
Revenue Per Share TTM
0.59
Quarterly Revenue Growth YOY
0.2%
Gross Profit TTM
2.2M
EBITDA
-2.0M
Diluted Eps TTM
-0.19
Quarterly Earnings Growth YOY
-0.95
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Company Financials

FY18Y/Y Change
Revenue
212.3K
-
Net Income
26.5K
-
Net Profit Margin
12.46%
-
FY19Y/Y Change
Revenue
127.0K
↓ 40.21%
Net Income
-246.5K
↓ 1031.69%
Net Profit Margin
-194.14%
↓ 206.6%
FY20Y/Y Change
Revenue
11.4M
↑ 8872.03%
Net Income
1.1M
↓ 543.91%
Net Profit Margin
9.61%
↑ 203.75%
FY21Y/Y Change
Revenue
13.4M
↑ 17.31%
Net Income
751.6K
↓ 31.31%
Net Profit Margin
5.62%
↓ 3.99%
FY22Y/Y Change
Revenue
10.9M
↓ 18.21%
Net Income
-356.0K
↓ 147.36%
Net Profit Margin
-3.26%
↓ 8.88%
FY23Y/Y Change
Revenue
9.8M
↓ 10.6%
Net Income
-2.6M
↑ 638.57%
Net Profit Margin
-26.91%
↓ 23.65%
Q4 FY22Q/Q Change
Revenue
2.8M
↑ 10.27%
Net Income
-157.0K
↑ 102.8%
Net Profit Margin
-5.53%
↓ 2.52%
Q1 FY23Q/Q Change
Revenue
2.4M
↓ 16.28%
Net Income
-69.1K
↓ 56.0%
Net Profit Margin
-2.91%
↑ 2.62%
Q2 FY23Q/Q Change
Revenue
2.6M
↑ 7.98%
Net Income
-259.3K
↑ 275.37%
Net Profit Margin
-10.1%
↓ 7.19%
Q3 FY23Q/Q Change
Revenue
2.6M
↓ 0.51%
Net Income
-2.6M
↑ 906.03%
Net Profit Margin
-102.13%
↓ 92.03%
Q4 FY23Q/Q Change
Revenue
2.3M
↓ 10.99%
Net Income
307.4K
↓ 111.79%
Net Profit Margin
13.52%
↑ 115.65%
Q1 FY24Q/Q Change
Revenue
2.3M
↑ 0.0%
Net Income
307.4K
↑ 0.0%
Net Profit Margin
13.52%
↑ 0.0%
FY18Y/Y Change
Total Assets
1.7M
-
Total Liabilities
130.3K
-
FY19Y/Y Change
Total Assets
1.2M
↓ 25.48%
Total Liabilities
108.9K
↓ 16.45%
FY20Y/Y Change
Total Assets
10.1M
↑ 721.56%
Total Liabilities
3.5M
↑ 3071.74%
FY21Y/Y Change
Total Assets
9.6M
↓ 5.35%
Total Liabilities
2.4M
↓ 30.65%
FY22Y/Y Change
Total Assets
8.7M
↓ 8.71%
Total Liabilities
2.1M
↓ 13.34%
FY23Y/Y Change
Total Assets
11.4M
↑ 30.43%
Total Liabilities
1.7M
↓ 16.06%
Q4 FY22Q/Q Change
Total Assets
8.7M
↑ 12.08%
Total Liabilities
2.1M
↑ 50.97%
Q1 FY23Q/Q Change
Total Assets
8.2M
↓ 6.33%
Total Liabilities
1.6M
↓ 21.46%
Q2 FY23Q/Q Change
Total Assets
7.9M
↓ 3.51%
Total Liabilities
1.9M
↑ 18.74%
Q3 FY23Q/Q Change
Total Assets
11.5M
↑ 45.15%
Total Liabilities
1.8M
↓ 8.13%
Q4 FY23Q/Q Change
Total Assets
11.4M
↓ 0.57%
Total Liabilities
1.7M
↓ 2.02%
Q1 FY24Q/Q Change
Total Assets
11.4M
↑ 0.0%
Total Liabilities
1.7M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-274.1K
↓ 176.73%
Investing Cash Flow
-51.7K
↓ 99.03%
Financing Cash Flow
742.9K
↓ 87.15%
FY19Y/Y Change
Operating Cash Flow
-217.3K
↓ 20.73%
Investing Cash Flow
-12.8K
↓ 75.21%
Financing Cash Flow
-180.8K
↓ 124.34%
FY20Y/Y Change
Operating Cash Flow
552.7K
↓ 354.37%
Investing Cash Flow
1.3M
↓ 10398.74%
Financing Cash Flow
-4.9K
↓ 97.26%
FY21Y/Y Change
Operating Cash Flow
9.2K
↓ 98.34%
Investing Cash Flow
-490.6K
↓ 137.16%
Financing Cash Flow
-28.2K
↑ 470.49%
Q4 FY22Q/Q Change
Operating Cash Flow
474.5K
↑ 54.47%
Investing Cash Flow
-3.1K
↓ 116.66%
Financing Cash Flow
0.0
↓ 100.01%
Q1 FY23Q/Q Change
Operating Cash Flow
-118.3K
↓ 124.93%
Investing Cash Flow
-5.1K
↑ 65.34%
Financing Cash Flow
-8.7K
↓ 7243433.33%
Q2 FY23Q/Q Change
Operating Cash Flow
-22.0K
↓ 81.37%
Investing Cash Flow
-3.1K
↓ 39.52%
Financing Cash Flow
-4.2K
↓ 51.54%

Technicals Summary

Sell

Neutral

Buy

Bionexus Gene Lab Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bionexus Gene Lab Corp
Bionexus Gene Lab Corp
11.72%
0.76%
-95.29%
-97.89%
-97.89%
Air Products & Chemicals Inc.
Air Products & Chemicals Inc.
-2.01%
2.28%
-10.72%
-5.5%
18.73%
Linde Plc
Linde Plc
0.77%
9.49%
19.04%
56.69%
119.31%
Dupont De Nemours Inc
Dupont De Nemours Inc
0.6%
9.05%
6.91%
10.36%
12.27%
Sherwin-williams Company, The
Sherwin-williams Company, The
8.0%
7.05%
21.44%
15.03%
113.84%
Ecolab Inc.
Ecolab Inc.
-0.66%
21.21%
29.36%
15.18%
22.81%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bionexus Gene Lab Corp
Bionexus Gene Lab Corp
NA
NA
NA
0.0
-0.33
-0.13
NA
0.53
Air Products & Chemicals Inc.
Air Products & Chemicals Inc.
24.1
24.1
1.37
12.25
0.16
0.05
0.03
67.08
Linde Plc
Linde Plc
34.61
34.61
2.65
15.49
0.16
0.07
0.01
80.78
Dupont De Nemours Inc
Dupont De Nemours Inc
89.05
89.05
1.64
3.63
0.02
0.03
0.02
56.41
Sherwin-williams Company, The
Sherwin-williams Company, The
34.73
34.73
4.16
11.38
0.72
0.1
0.01
13.88
Ecolab Inc.
Ecolab Inc.
45.06
45.06
2.33
6.57
0.2
0.07
0.01
23.46
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bionexus Gene Lab Corp
Bionexus Gene Lab Corp
NA
$9.4M
-97.89%
NA
-27.25%
Air Products & Chemicals Inc.
Air Products & Chemicals Inc.
Buy
$59.3B
18.73%
24.1
20.32%
Linde Plc
Linde Plc
Buy
$214.3B
119.31%
34.61
19.26%
Dupont De Nemours Inc
Dupont De Nemours Inc
Buy
$34.3B
12.27%
89.05
2.96%
Sherwin-williams Company, The
Sherwin-williams Company, The
Buy
$82.6B
113.84%
34.73
10.52%
Ecolab Inc.
Ecolab Inc.
Hold
$69.5B
22.81%
45.06
10.01%

Insights on Bionexus Gene Lab Corp

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 2.56M → 2.27M (in $), with an average decrease of 3.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -2.60M → 307.41K (in $), with an average increase of 474.2% per quarter

  • Vs ECL

    In the last 1 year, Ecolab Inc. has given 29.4% return, outperforming this stock by 124.7%

Company Information

Organization
Bionexus Gene Lab Corp
Employees
30
CEO
Mr. Su-Leng Tan
Industry
Commercial Services

FAQs